Payment overview · 2025
General Payments
$679.87
16 reported records · 7 companies
Healthcare provider profile · identity verified
Ram Subbureddiar, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · TUCSON, AZ · NPI 1326016221
Verified facts
What the public records show
CMS Open Payments records show Ram Subbureddiar, MD received $679.87 in general payments during 2025 across 16 reported records.
Amgen Inc. accounted for 31.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $210.53 | 31.0% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $172.74 | 25.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $125.00 | 18.4% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $121.51 | 17.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.37 | 3.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.80 | 2.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.92 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $679.87 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $159.20 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $121.51 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $121.51 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $51.33 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $47.74 | 2 | 2025 |
Source payment records
|
|||||
| BYETTA Normalized: byetta |
Drug | AstraZeneca Pharmaceuticals LP | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $10.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
113 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 494 | 126 |
| Levothyroxine Sodium | Levothyroxine Sodium | 425 | 89 |
| Gabapentin | Gabapentin | 357 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 345 | 89 |
| Metformin Hcl | Metformin Hcl | 314 | 77 |
| Lisinopril | Lisinopril | 282 | 76 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 269 | 63 |
| Oxycodone Hcl | Oxycodone Hcl | 262 | 28 |
| Furosemide | Furosemide | 244 | 66 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 236 | 25 |
| Omeprazole | Omeprazole | 232 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 193 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 162 | 19 |
| Potassium Chloride | Potassium Chloride | 154 | 39 |
| Losartan Potassium | Losartan Potassium | 151 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 146 | 25 |
| Ibuprofen | Ibuprofen | 128 | 40 |
| Mirtazapine | Mirtazapine | 125 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 121 | 29 |
| Trazodone Hcl | Trazodone Hcl | 120 | 23 |
| Azithromycin | Azithromycin | 115 | 65 |
| Januvia | Sitagliptin Phosphate | 115 | 20 |
| Eliquis | Apixaban | 113 | 21 |
| Allopurinol | Allopurinol | 111 | 20 |
| Glipizide | Glipizide | 105 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 28 |
| Alprazolam | Alprazolam | 95 | 18 |
| Morphine Sulfate Er | Morphine Sulfate | 92 | 11 |
| Alendronate Sodium | Alendronate Sodium | 86 | 27 |
| Carvedilol | Carvedilol | 84 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 79 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 19 |
| Lorazepam | Lorazepam | 78 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 16 |
| Pregabalin | Pregabalin | 77 | 12 |
| Donepezil Hcl | Donepezil Hcl | 76 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 19 |
| Jardiance | Empagliflozin | 75 | 13 |
| Simvastatin | Simvastatin | 75 | 23 |
| Famotidine | Famotidine | 71 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 17 |
| Spironolactone | Spironolactone | 62 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 13 |
| Ozempic | Semaglutide | 60 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 59 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 15 |
| Methocarbamol | Methocarbamol | 47 | suppressed |
| Atenolol | Atenolol | 46 | 11 |
| Cephalexin | Cephalexin | 45 | 26 |
| Gemtesa | Vibegron | 45 | 12 |
| Temazepam | Temazepam | 45 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Ondansetron Odt | Ondansetron | 43 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 34 |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 40 | suppressed |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | suppressed |
| Acyclovir | Acyclovir | 35 | suppressed |
| Baclofen | Baclofen | 35 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 34 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | 12 |
| Glimepiride | Glimepiride | 31 | suppressed |
| Prednisone | Prednisone | 31 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Carbamazepine Er | Carbamazepine | 29 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 12 |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 17 |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Erythromycin | Erythromycin Base | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 12 |
| Mupirocin | Mupirocin | 18 | 14 |
| Tradjenta | Linagliptin | 18 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 12 |
| Lovastatin | Lovastatin | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Methadone Hcl | Methadone Hcl | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $679.87 · 16 records | Amgen Inc. | ABRYSVO, BREZTRI, BYETTA, CAPLYTA, COMIRNATY, CT THROMBECTOMY SYSTEM KIT, EVENITY, FLOWTRIEVER CATHETER, S, OTEZLA, Ozempic, PREVNAR 20, REPATHA, REXULTI, TEZSPIRE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error